Investors
Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris


Press Releases
2023
13/01/2023 : Bilan semestriel du contrat de liquidité contractée avec CM-CIC Securities. (Frenche version)
05/01/2023 : Genomic Vision annonces succesful Beta Testing of FiberSmart®
2022
22/12/2022: Our reflections on 2022 and what 2023 holds (Shareholders letter)
29/11/2022: Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research
Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer®
24/10/2022: Genomic Vision: press release regarding changes in the Company’s governance
29/09/2022: First Half 2022 Results
22/07/2022 : Financial information for the First Half of 2022
13/07/2022: Genomic Vision: changes in the Company’s governance
23/06/2022 : Genomic Vision obtains the renewal of the ISO 13485: 2016 certification
8/06/2022 – Mise à disposition des documents préparatoires et modalités de participation et de vote à l’AGO du 28 juin 2022. (French document, General Assembly part)
05/05/2022: Financial Information for the First Quater of 2022.
02/05/2022: Availability of preparatory documents and participation and voting procedures for the extraordinary general meeting of shareholders on May 23, 2022. French documents (General Assembly part)
28/04/2022 : Availability of the 2021 annual financial report French version
21/04/2022 : Financial information: Annual Results 2021
11/04/2022: New Financing Line with Winance, Subject to Prior Approval of the Company’s Shareholders
15/02/2022: Financial Information for the Fourth Quater of 2021
2021
24/12/2021: Financial information, 2 new tranches of convertible notes with warrants for 2M€
28/10/2021: Financial Information for the Third Quarter 2021
19/10/202: Genomic Vision announces TeloSizer® Triathlon program to provide academic researchers with an access path to molecular combing telomere services
13/10/2021: Appointment of Thierry Huet as R&D Director
28/09/2021: Genomic Vision launches TeloSizer® for precise detection and quantitative measurement of telomere length
29/07/2021: First-half 2021 results
10/06/2021: 2nd call for OGM on June 30, 2021
17/05/2021: Financial Information for the First Quarter of 2021
14/05/2021: Partnership with SANOFI
29/04/2021 : Financial information: Annual Results 2020
14/04/2021 : Appointment of Mark David Lynch as Global Commercial and Marketing Director
18/02/2021 : Financial Information for the Fourth Quarter of 2020
12/01/2021 : French documentation “Bilan Semestriel du contrat de liquidité S2 2020”
2020
24/11/2020 : Issuance of the first tranche of convertible notes with warrants (OCABSA)
12/11/2020 : Financial Information for the Third Quarter of 2020
13/10/2020 : Genomic Vision signs a distribution agreement for Covid-19 rapid diagnostic tests with Toda Pharma
29/09/2020 : First Half Results
22/09/2020 : Genomic Vision: convening of another Extraordinary General Meeting on October 30, 2020
24/07/2020 : Genomic Vision: convening of a new Combined Shareholders’ Meeting on August 10, 2020
20/07/2020 : Financial Information for the First Half of 2020
09/07/2020 : Half-yearly balance of the Liquidity Agreement with CM-CIC Securities
06/07/2020 : Press release on the availability of the 2019 annual financial report
06/07/2020 : Press release on the availability of the preparatory documents for the AGM of 24 July 2020
29/05/2020: Financial information for the 1st quarter of 2020
21/05/2020: Financial information: FYR 2019
18/05/2020 : Financial information : Drawdown of the 4th tranche
30/04/2020 : Financial information
09/04/2020 : Genomic Vision strenghtens its governance
13/02/2020 : Dana Farber Cancer Institute adopts Genomic Vision’s platform including the FiberVisionS
11/02/2020 : Financial information
30/01/2020 : Q4 2019 Financial information
21/01/2020 : Genomic Vision’s technology to be tested by the NIST
15/01/2020 : Strategic Partnership between Genomic Vision and GIPTIS
2019
30/10/2019 : Q3 2019 Financial information
21/10/2019 : Promising results for the TLA assay
25/10/2019 : Genomic Vision’s platform installed at the NIH
24/09/2019 : Financial information for the First Half of 2019
26/07/2019 : Financial information for the First Half of 2019: turnover and cash position
22/07/2018 : Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)
09/07/2019 : Genomic Vision reports of the Combined Shareholders’ Meeting of July 8, 2019
21/06/2019 : Second convening of Shareholders meeting of July 8, 2019
02/05/2019: Financial information for the First Quarter of 2019
26/03/2019 : Genomic Vision announces the signing of the financing contract with Winance
06/03/2019 : 2018 Annual Results
18/02/2019 : Genomic Vision: convening of another Extraordinary Shareholders’ Meeting on March 4, 2019
08/02/2019 : Genomic Vision: Oxford University selects the molecular combing technology to study DNA replication in the context of a rare disease
06/02/2019 : Financial information for the Fourth Quarter of 2018
11/01/2019 : Bilan semestriel du contrat de liquidités contracté avec CM-CIC Securities (in French)
2018
22/11/2018 : Genomic Vision signs a licensing agreement with Phyteneo on HPV integration test in Czech Republic
29/10/2018 : Genomic Vision: positive results of the clinical study EXPL-HPV-002 in cervical cancer detection
24/10/2018 : Financial information for the Third Quarter of 2018
28/09/2018 : First Semester Financial Report 2018 (in French)
10/09/2018 : Genomic Vision achieves second milestone with Quest Diagnostics on SMA carrier testing
09/08/2018
Genomic Vision and European Equity Partners enter into agreement to use molecular combing as a genome integrity assay in the field of biomanufacturing
06/08/2018
Genomic Vision: new perspectives in the genomic analysis of plants
25/07/2018
First half 2018 results
17/07/2018
Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)
05/07/2018
Genomic Vision provides an update on its commercial development and financial situation
19/06/2018
Compte rendu de l’assemblée générale mixte du 19 juin 2018 (in French)
11/06/2018
Genomic Vision: the performances of the FSHD diagnostic assay presented at the 2018 International FSHD Research Conference (IRC) in Las Vegas
29/05/2018
All documents for the shareholders’ meeting of June 19, 2018 are available on Genomic Vision website (in French only)
16/05/2018
Genomic Vision enters into a strategic research collaboration with Children’s Medical Research Institute (CMRI) on telomere length assay
02/05/2018
Genomic Vision invited to present molecular combing at Genopole
27/04/2018
Financial Information for the First Quarter of 2018
26/04/2018
Provision of the 2017 Financial Annual Report (in French only)
24/04/2018
Genomic Vision invited to present FiberVision platform at the Nist-FDA Genome Editing workshop in Gaithersburg (Maryland)
21/03/2018
2017 Annual Results
14/03/2018
Genomic Vision extends its collaboration with Quest Diagnostics in spinal muscular atrophy (SMA)
17/01/2018
2017 Annual revenue from sales: +36% to €2.1 million
04/01/2018
Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French only)
19/12/2017
Genomic Vision optimizes the terms of its OCABSA (Convertible Notes with Warrants) financing line to obtain greater flexibility within the framework of its development
13/11/2017
All documents for the shareholders’ meeting of December 4, 2017 are available on Genomic Vision website (in French only)
24/10/2017
Financial information at Sept 30, 2017
19/10/2017
Genomic Vision signs a distribution agreement with AmCare Genomics Laboratory in China for its FSHD diagnostic assay
11/10/2017
Genomic Vision presented the interim results of its clinical trial in cervical cancer screening at the Eurogin annual congress
27/07/2017
Molecular combing featured in an oral presentation on CRISPR/Cas9 gene editing at the 3rd CSHL meeting in New York
12/07/2017
The Cologne Center for Genetics (CCG), a major European core facility in genetic analyis, adopts the molecular combing technology
30/05/2017
All documents for the shareholders’ meeting of June 20, 2017 are available on Genomic Vision website (in French only)
30/05/2017
Genomic Vision declares its eligibility to the French tax regime PEA-PME for 2017/2018 (in French only)
10/05/2017
Genomic Vision announces promising preliminary results for its clinical study in cervical cancer detection
01/03/2017
2016 annual results in line with the successful execution of the new strategy in LSR market
28/10/2016
Financial information at September 30, 2016 and implementation of a flexible financing via the reserved issuance of convertible notes with warrants
20/07/2016
Genomic Vision is accelerating its clinical trial in cervical cancer with an additional study in the Czech Republic
11/07/2016
Genomic Vision launches EasyScan, the first digital service for analyzing DNA by molecular combing
16/06/2016
The clinical trial led by Genomic Vision and Reims University Hospital presented at the Eurogin Congress
08/02/2016
Genomic Vision to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
18/01/2016
2015 sales in line with expectations after all planned milestones with Quest Diagnostics were met
14/01/2016
Genomic Vision to demonstrate ‘molecular combing’ technology’s ability to identify novel cancer-causing BRCA gene variants
11/01/2016
Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments
14/12/2015
Genomic Vision and Reims University Hospital Launch Clinical Study to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer
03/12/2015
Genomic Vision signs a strategic partnership with the Imagine Institute, the largest European genetic research and care cluster
12/11/2015
GENOMIC VISION to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum
15/10/2015
GENOMIC VISION and ROUEN University Hospital launch a trial to improve genetic counseling for Infantile Spinal Muscular Atrophy in France
09/06/2015
Genomic Vision selected for the Horizon 2020 program’s ‘BeyondSeq’ project with a total grant of €6 million
15/03/2015
2014 annual results in line with the Company’s buoyant development
Total revenue from activity: €4.9 million
Operating costs under control
Solid cash position of €22.8 million
17/02/2015
Genomic Vision renews its Strategic Collaboration with Quest Diagnostics for three more years

